Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.
A promising approach to developing a vaccine against O111 strains of diarrheagenic Escherichia coli that exhibit different mechanisms of virulence is to target either the core or the polysaccharide chain (O antigen) of their lipopolysaccharide (LPS). However, due to structural variations found in both these LPS components, to use them as antigen targets for vaccination, it is necessary to formulate a vaccine able to induce a humoral immune response that can recognize all different variants found in E. coli O111 strains. In this study, it was demonstrated that, despite differences in composition of oligosaccharide repeat units between O111ab and O111ac LPS subtypes, antibodies against one O111 subtype can recognize and inhibit the adhesion to human epithelial cells of all categories of O111 E. coli (enteropathogenic E. coli [EPEC], enterohemorrhagic E. coli [EHEC], and enteroaggregative E. coli [EAEC]) strains regardless of the nature of their flagellar antigens, mechanisms of virulence, or O111 polysaccharide subtypes. These antibodies were also able to increase the clearance of different strains of O111 E. coli by macrophages. PCR analyses of the pathways involved in O111 LPS core biosynthesis showed that all EAEC strains have core type R2, whereas typical EPEC and EHEC have core type R3. In contrast, atypical EPEC strains have core types R2 and R3. In summary, the results presented herein indicate that the O111 polysaccharide and LPS core types R2 and R3 are antigen targets for panspecific immunotherapy against all categories of O111 E. coli.
Santos
Maurílio F
MF
Laboratory of Bacteriology, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, CEP 05503-900, São Paulo, Brazil.
New
Roger R C
RR
Andrade
Gabrielle R
GR
Ozaki
Christiane Y
CY
Sant'Anna
Osvaldo A
OA
Mendonça-Previato
Lucia
L
Trabulsi
Luis R
LR
Domingos
Marta O
MO
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology*; D001422:Bacterial Adhesion / Q000276:immunology; D002460:Cell Line; D004847:Epithelial Cells / Q000382:microbiology; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control*; D022361:Escherichia coli Vaccines / Q000276:immunology*; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology*; D008264:Macrophages / Q000276:immunology / Q000382:microbiology; D051379:Mice; D011817:Rabbits
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D022361:Escherichia coli Vaccines; D008070:Lipopolysaccharides